APA

Colozza M., Sidoni A., Mosconi A. M., Cavaliere A., Bisagni G., Gori S., De Angelis V., Frassoldati A., Cherubini R., Bian A. R., Rodino C., Mazzocchi B., Mihailova Z., Bucciarelli E. & Tonato M. (20051207). HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. : Clinical breast cancer.

Chicago

Colozza Mariantonietta, Sidoni Angelo, Mosconi Anna Maria, Cavaliere Antonio, Bisagni Giancarlo, Gori Stefania, De Angelis Verena, Frassoldati Antonio, Cherubini Roberta, Bian Alberto Rosa, Rodino Carmelina, Mazzocchi Bruno, Mihailova Zhasmina, Bucciarelli Emilio and Tonato Maurizio. 20051207. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. : Clinical breast cancer.

Harvard

Colozza M., Sidoni A., Mosconi A. M., Cavaliere A., Bisagni G., Gori S., De Angelis V., Frassoldati A., Cherubini R., Bian A. R., Rodino C., Mazzocchi B., Mihailova Z., Bucciarelli E. and Tonato M. (20051207). HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. : Clinical breast cancer.

MLA

Colozza Mariantonietta, Sidoni Angelo, Mosconi Anna Maria, Cavaliere Antonio, Bisagni Giancarlo, Gori Stefania, De Angelis Verena, Frassoldati Antonio, Cherubini Roberta, Bian Alberto Rosa, Rodino Carmelina, Mazzocchi Bruno, Mihailova Zhasmina, Bucciarelli Emilio and Tonato Maurizio. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. : Clinical breast cancer. 20051207.